Bristol Myers Squibb Receives European Commission Approval of Sotyktu (Deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

Key Takeaways

• EU approves Sotyktu, first TYK2 inhibitor for psoriatic arthritis
• Phase 3 trials showed 20% absolute ACR20 improvement vs placebo
• Safety profile aligns with plaque psoriasis data, common mild infections
• Can be used alone or combined with methotrexate
• Expands Bristol Myers Squibb's immunology portfolio in Europe

Pulse Analysis

The European Commission’s endorsement of Sotyktu marks a pivotal regulatory milestone for oral TYK2 inhibition. As the first drug of its class approved for psoriatic arthritis in the EU, it differentiates itself from traditional JAK inhibitors by targeting a distinct signaling node, potentially mitigating some of the cardiovascular and thrombotic concerns that have shadowed the JAK space. This approval broadens therapeutic options for rheumatologists, who now have a once‑daily pill that can address both joint inflammation and skin lesions, a dual benefit that many biologics struggle to deliver.

Clinical data underpinning the decision are compelling. In the POETYK PsA‑1 and POETYK PsA‑2 trials, 54% of patients on Sotyktu achieved an ACR20 response at week 16, outpacing placebo by roughly 20 percentage points. Minimal Disease Activity rates also rose by 9‑11 points, and quality‑of‑life scores (SF‑36 PCS) improved and persisted through week 52. The safety signal remained consistent with earlier psoriasis studies, with upper‑respiratory infections and mild laboratory abnormalities being the most frequent adverse events, reinforcing confidence in its tolerability for long‑term use.

For Bristol Myers Squibb, the EU clearance expands an already robust immunology pipeline and positions the company to capture market share from both biologic injectables and oral JAK inhibitors. The approval may also pave the way for additional indications, as the firm signals intent to explore Sotyktu in other serious rheumatic conditions. Payers will likely evaluate cost‑effectiveness against existing therapies, but the oral administration route and favorable safety profile could drive rapid uptake, especially among patients seeking alternatives to injectable regimens.